Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.

[1]  P. Alonso-Coello,et al.  WITHDRAWN: Radioisotopes for metastatic bone pain. , 2017, The Cochrane database of systematic reviews.

[2]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[3]  John D. Roberts,et al.  CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. , 2015 .

[4]  Liang Chen,et al.  Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials , 2015, Osteoporosis International.

[5]  S. Fosså,et al.  Effects of strength training on body composition, physical functioning, and quality of life in prostate cancer patients during androgen deprivation therapy , 2015, Acta oncologica.

[6]  F. Saad,et al.  The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC). , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[7]  B. Zimmerman,et al.  Revision of the NIST Standard for 223Ra: New Measurements and Review of 2008 Data , 2015, Journal of research of the National Institute of Standards and Technology.

[8]  Kurt Miller,et al.  Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). , 2015, European urology.

[9]  S. Chambers,et al.  Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen‐deprivation therapy: a randomised controlled trial , 2015, BJU international.

[10]  Z. Weng,et al.  Docetaxel with or without zoledronic acid for castration-resistant prostate cancer , 2014, International Urology and Nephrology.

[11]  J. A. Bennett,et al.  Skeletal response to resistance and impact training in prostate cancer survivors. , 2014, Medicine and science in sports and exercise.

[12]  S. Fosså,et al.  Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. , 2014, The Lancet. Oncology.

[13]  F. Saad,et al.  Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Kachnic,et al.  RTOG 0518: Randomized Phase III Trial to Evaluate Zoledronic Acid for Prevention of Osteoporosis and Associated Fractures in Prostate Cancer Patients , 2013, Prostate Cancer and Prostatic Disease.

[15]  S. Horie,et al.  Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study. , 2013, Anticancer research.

[16]  Z. Weng,et al.  Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases , 2013, Medical Oncology.

[17]  I Syndikus,et al.  Alpha emitter radium-223 and survival in metastatic prostate cancer. , 2013, The New England journal of medicine.

[18]  C. Parker,et al.  Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. , 2013, Clinical genitourinary cancer.

[19]  Rashmi Kumar,et al.  NCCN Task Force Report: Bone Health in Cancer Care. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

[20]  Zhi-Ping Wang,et al.  Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[21]  P. Royle,et al.  Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis. , 2013, European journal of cancer.

[22]  O. Dalesio,et al.  Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). , 2012, European journal of cancer.

[23]  J. Trachtenberg,et al.  Group Exercise versus Personal Training for Prostate Cancer Patients: A Pilot Randomized Trial , 2012 .

[24]  F. Saad,et al.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial , 2012, The Lancet.

[25]  Ehud Mendel,et al.  Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. , 2011, International journal of radiation oncology, biology, physics.

[26]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[27]  David A Hanley,et al.  2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary , 2010, Canadian Medical Association Journal.

[28]  C. Loprinzi,et al.  Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8 , 2010, Supportive Care in Cancer.

[29]  M. Parmar,et al.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials , 2009, The Lancet. Oncology.

[30]  F. Saad,et al.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer. , 2009, The New England journal of medicine.

[31]  S. Baba,et al.  Single infusion of zoledronic acid to prevent androgen deprivation therapy‐induced bone loss in men with hormone‐naive prostate carcinoma , 2009, Cancer.

[32]  S. Perera,et al.  Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  P. Tugwell,et al.  Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. , 2024, The Cochrane database of systematic reviews.

[34]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[35]  M. Parmar,et al.  Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). , 2007, Journal of the National Cancer Institute.

[36]  P. Rodrigues,et al.  Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open‐label controlled study , 2007, International journal of urology : official journal of the Japanese Urological Association.

[37]  J. Gottesman,et al.  The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. , 2007, Clinical genitourinary cancer.

[38]  T. Wilt,et al.  Bisphosphonates for advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.

[39]  S. Nilsson,et al.  Palliation of bone pain in prostate cancer using chemotherapy and strontium-89. A randomized phase II study. , 2005, Journal of pain and symptom management.

[40]  S. Steinberg,et al.  A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. , 2005, The Journal of urology.

[41]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[42]  E. Small,et al.  Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  L. Collette,et al.  Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group , 2003 .

[44]  M. Parmar,et al.  A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). , 2003, Journal of the National Cancer Institute.

[45]  I. Tannock,et al.  Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  L. Collette,et al.  Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. , 2003, European urology.

[47]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[48]  P. de Souza,et al.  The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade , 2001, Cancer.

[49]  M. Carey,et al.  Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A Gafni,et al.  The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D P Dearnaley,et al.  A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  T. Tammela,et al.  Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the Finnish Prostate Cancer Group. , 1993, European journal of cancer.